Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Hospices Civils de Lyon
Radio Isotope Therapy of America
Hoffmann-La Roche
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Intergroupe Francophone de Cancerologie Thoracique
Peking University
Hoffmann-La Roche
The Christie NHS Foundation Trust
UNICANCER
Catholic University of the Sacred Heart
SCRI Development Innovations, LLC
National Cancer Institute (NCI)
SCRI Development Innovations, LLC
Asan Medical Center
Xencor, Inc.
Institut Curie
M.D. Anderson Cancer Center
Sunnybrook Health Sciences Centre
Johannes Gutenberg University Mainz
Tarveda Therapeutics
Boston Scientific Corporation
Novartis
AIO-Studien-gGmbH
National Cancer Institute, Naples
Ohio State University Comprehensive Cancer Center
Sunnybrook Health Sciences Centre
Samsung Medical Center
Haukeland University Hospital
Gabrail Cancer Center Research
National Health Research Institutes, Taiwan
National Institutes of Health Clinical Center (CC)
University of Manitoba
Yale University
Vanderbilt-Ingram Cancer Center
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Novartis
University of Western Ontario, Canada
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Callisto Pharmaceuticals
Mannkind Corporation
University of Turin, Italy
Callisto Pharmaceuticals